Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04276376
Title Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

prostate cancer

Advanced Solid Tumor

gastroesophageal junction adenocarcinoma

lung non-small cell carcinoma

clear cell renal cell carcinoma

bladder urothelial carcinoma

gastric adenocarcinoma


Atezolizumab + Rucaparib

Age Groups: senior | adult
Covered Countries FRA

Additional content available in CKB BOOST